Session » Vasculitis
-
Abstract Number: 775
HLA-DRB1 Alleles in Susceptibility to Giant Cell Arteritis: Literature Review and Meta-Analysis
-
Abstract Number: 776
A Candidate Gene Approach Identifies IL33 as a Novel Genetic Risk Factor for GCA
-
Abstract Number: 777
Influence of the IL17A Locus in Giant Cell Arteritis Susceptibility
-
Abstract Number: 778
PTPN22 rs2476601 and Susceptibility to Biopsy Proven Giant Cell Arteritis (GCA) in an Australian Sample
-
Abstract Number: 779
Toll-like Receptor 2 Agonism Induces Inflammation, Angiogenesis and Cell Migration in Giant Cell Arteritis
-
Abstract Number: 780
Novel Roles for Zyxin in the Pathogenesis of Giant Cell Arteritis
-
Abstract Number: 781
Rho Kinase (ROCK) Activity in Aortitis: Comparison of Giant Cell Arteritis (GCA), Takayasu Arteritis (TA) and Isolated Aortitis (IA)
-
Abstract Number: 782
Temporal Artery Microbiome in Giant Cell Arteritis
-
Abstract Number: 783
Increased Migration and Proliferation Potential Characterize Vascular Smooth Muscle Cells from Patients with Giant Cell Arteritis
-
Abstract Number: 784
Novel Inhibitory Effects of Mast Cells in Aortitis Involves Aortic Expression of Suppressor of Cytokine Signaling-1
-
Abstract Number: 785
Incidence, Prevalence and Survival of Biopsy-Proven Giant Cell Arteritis in Northern Italy
-
Abstract Number: 786
The Incidence and Mortality Rates of Giant Cell Arteritis in Southern Norway Are Lower Than Previous Reported
-
Abstract Number: 787
Cardiovascular Risk Factors and Incident Giant Cell Arteritis
-
Abstract Number: 788
Fast-Track Diagnostic Procedure for Giant Cell Arteritis
-
Abstract Number: 789
Association Between Histological Features and Clinical Features of Patients with Biopsy Positive Giant Cell Arteritis
-
Abstract Number: 790
Correlations Between Histopathological Findings and Clinical Manifestations in a Large Monocentric Cohort of Patients with Biopsy-Proven Giant Cell Arteritis
-
Abstract Number: 791
Comparison of Clinical Manifestations in Different Histological Subsets of Biopsy-Proven Giant Cell Arteritis
-
Abstract Number: 792
Is Temporal Artery Biopsy the Gold Standard for the Diagnosis of Giant Cell Arteritis?
-
Abstract Number: 793
Preliminary Analysis of Histological Findings in Diagnosis of Giant Cell Arteritis Biopsy Positive Patients
-
Abstract Number: 794
Color Doppler Ultrasonography Findings in Giant Cell Arteritis and Their Relationship with Clinical Manifestations
-
Abstract Number: 795
High Interobserver Agreement on Ultrasonographic Findings in Patients with Large Vessel Vasculitis
-
Abstract Number: 796
Early Halo Sign Features on Ultrasound Examination of Treated Patients with Giant Cell Arteritis
-
Abstract Number: 797
PET/CT for the Diagnosis of Giant Cell Arteritis: A Prospective Study
-
Abstract Number: 798
Frequency and Predictive Variables of Relapses in Patients with Biopsy-Proven Giant Cell Arteritis
-
Abstract Number: 799
Peripheral Arterial Disease in Patients with Giant Cell Arteritis: A Systematic Review and Meta-Analysis
-
Abstract Number: 800
Hospitalization Rates and Utilization Among Patients with Giant Cell Arteritis: A Population-Based Study from 1987 to 2012
-
Abstract Number: 801
Venothromboembolism in Large Vessel Vasculitis
-
Abstract Number: 802
Inpatient Complications in Patients with Giant Cell Arteritis: Increased Risk of Thromboembolism, Delirium and Adrenal Insufficiency
-
Abstract Number: 803
Corticosteroid-Related Adverse Events in Patients with Giant Cell Arteritis: A Claims-Based Analysis
-
Abstract Number: 804
Vasculitis and Inflammatory Bowel Diseases: A Study of 32 Patients with Both Conditions and Systematic Review of the Literature
-
Abstract Number: 805
Takayasu Arteritis and Ulcerative Colitis –High Concurrence Ratio and Genetic Overlap
-
Abstract Number: 806
Association of a Single Nucleotide Polymorphism (SNP) in IL-12B Region with Clinical Features and Peripheral T Cell Profiles of Patients with Takayasu Arteritis
-
Abstract Number: 807
Serum Cytokine Profiles in Takayasu’s Arteritis: A Search for a Biomarker
-
Abstract Number: 808
Biomarkers of Disease Activity in Vasculitis
-
Abstract Number: 809
Risk Factors for Severe Ischemic Complications in Takayasu Arteritis: A French Multicenter Retrospective Cohort of 182 Patients
-
Abstract Number: 810
Damage Assessment in Takyasu Arteritis Using Takayasu Arteritis Damage Score (TADS)
-
Abstract Number: 811
Biologics in Takayasu Arteritis: Preliminary Data from the French Registry
-
Abstract Number: 812
Prognosis of Clinically Inactive Takayasu’s Arteritis
-
Abstract Number: 813
Long-Term Outcomes of Takayasu’s Arteritis Patients with Renal Artery Involvement
-
Abstract Number: 814
Tocilizumab in Giant Cell Arteritis: Multicenter Open-Label Study of 22 Patients
-
Abstract Number: 1754
Peripheral CD5+ b-Cells in ANCA-Associated Vasculitis
-
Abstract Number: 1755
Proteomic Analysis of ANCA Vasculitis Serum Reveals Broad Neutrophil Activation, Angiogenesis, and Selective Inflammatory Pathway Activation
-
Abstract Number: 1756
Molecular Diagnosis Reveals a Surprising Prevalence of Limited Gpa Among Patients with Orbital Inflammatory Diseases
-
Abstract Number: 1757
An Analysis of the Incidence and Characteristics of ANCA Positive Vasculitis before and after the Christchurch Earthquake
-
Abstract Number: 1758
Environmental Risk Factors for Granulomatous Polyangiitis (GPA): Southern Hemisphere Similar to Northern Hemisphere
-
Abstract Number: 1759
Analysis of Employment, Work Disability and Quality of Life of Patients with ANCA-Associated Vasculitis
-
Abstract Number: 1760
United Kingdom & Ireland Vasculitis Registry – Cross-Sectional Data on the First 1085 Patients
-
Abstract Number: 1761
Standardisation of Disease Assesment in Systemic Vasculitis: Use of a Novel Web-Based Software Training Application
-
Abstract Number: 1762
The Muscle Biopsy Is a Useful and Noninvasive Procedure in Diagnosing Systemic Vasculitis Affecting Small-to-Medium-Sized Vessels: A Prospective Evaluation
-
Abstract Number: 1763
Tobacco Differentially Affects the Clinical-Biological Phenotype of ANCA-Associated Vasculitides at Diagnosis
-
Abstract Number: 1764
Clinical and Other Differences Observed Between Cocaine Induced and Non-Cocaine Induced Anti-Neutrophil Cytoplasmic Antibody Positive Vasculitis
-
Abstract Number: 1765
Comparison of Clinical Characteristics of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis By the Serotype Specificity to Myeloperoxidase and Proteinase-3
-
Abstract Number: 1766
Comparison of Clinicopathologically- and Serologically-Based Classification Systems for ANCA-Associated Vasculitis
-
Abstract Number: 1767
Granulomatosis with Polyangiitis (Wegener’s) According to Geographic Origin and Ethnicity: Clinical-Biological Presentation and Outcome
-
Abstract Number: 1768
Cardiac Involvement in Granulomatosis with Polyangiitis: A Magnetic Resonance Imaging Study of 31 Consecutive Patients
-
Abstract Number: 1769
Abdominal Visceral Adipose Tissue Measured By DXA As a Novel Surrogate Marker of Cardiovascular Risk in Primary Necrotizing Vasculitides
-
Abstract Number: 1770
Increased Risk of Chronic Obstructive Pulmonary Disease in Granulomatosis with Polyangiitis: A General Population-Based Study
-
Abstract Number: 1771
Arterial Thrombotic Events in Systemic Vasculitis
-
Abstract Number: 1772
Venous Thromboembolic Events in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
-
Abstract Number: 1773
Otolaryngologic Lesions Are Not Rare and Closely Related with Pachymeningitis and Cranial Neuropathy in MPO-ANCA Associated Vasculitis
-
Abstract Number: 1774
Granulomatosis with Polyangiitis (Wegener’s): Endoscopic Management of Tracheobronchial Stenosis – Results from a Multicenter Experience in 47 Patients
-
Abstract Number: 1775
Predicting Relapse in Patients with Granulomatosis with Polyangiitis – the Potential Use of Monitoring in Vitro ANCA Production
-
Abstract Number: 1776
Factors Predictive of ANCA-Associated Vasculitis Relapse in Patients Given Rituximab-Maintenance Therapy
-
Abstract Number: 1777
Staphylococcus Aureus Nasal Carriage and Relapses, Bvas, ANCA-Positivity and Cotrimoxazole Use in ANCA-Associated Vasculitis
-
Abstract Number: 1778
Rituximab Versus Azathioprine for ANCA-Associated Vasculitis Maintenance Therapy: Impact in Health-Related Quality of Life
-
Abstract Number: 1779
Plasmapheresis Therapy in ANCA-Associated Vasculitides: A Single-Center Retrospective Analysis of Renal Outcome and Mortality
-
Abstract Number: 1780
Outcomes of Triple Therapy (Plasma Exchange, Cyclophosphamide and Systemic Corticosteroid) for Anti-Neutrophil Cytoplasm Antibody (ANCA)-Associated Vasculitis
-
Abstract Number: 1781
Long-Term Outcomes Among Patients with Renal Disease Secondary to ANCA-Associated Vasculitis: Temporal Trends over 25 Years
-
Abstract Number: 1782
Long-Term Follow-up of Non-HBV Polyarteritis Nodosa and Microscopic Polyangiitis with Poor-Prognosis Factors
-
Abstract Number: 1783
The Importance of Histopathological Classification of ANCA-Associated Glomerulonephritis in Renal Function and Renal Survival
-
Abstract Number: 1784
Prognostic Factors for Interstitial Lung Disease with Microscopic Polyangiitis
-
Abstract Number: 1785
Survival of Microscopic Polyangiitis (MPA) Patients with and without Pulmonary Fibrosis (PF)
-
Abstract Number: 1786
Vasculitis As Underlying Cause of Death in the United States: 1999 – 2010
-
Abstract Number: 1787
HLA-DRB1*01 Is Associated with Henoch- Schönlein Purpura in the Spanish Population
-
Abstract Number: 1788
Association of HLA-B*41 with Henoch-Schönlein Purpura in Spanish Individuals Irrespective of the HLA-DRB1 Status
-
Abstract Number: 1789
Are EULAR/Printo/PRES Classification Criteria Appropriate for Classification of IgA Vasculitis in Adults?
-
Abstract Number: 1790
Follow up of an Unselected IgA Vasculitis (Henoch-Schönlein Purpura) Population at Single Rheumatology Center
-
Abstract Number: 1791
Applicability of the 2006 European League Against Rheumatism (EULAR) Criteria for the Classification of Henoch-Schönlein Purpura. an Analysis Based on 766 Patients with Cutaneous Vasculitis
-
Abstract Number: 1792
Clinical-Biological and Pathological Spectrum and Outcome of IgA Vasculitis in Adults: A French Study
-
Abstract Number: 1793
Efficacy and Safety of IFN-Alpha in Induction and Maintenance of Remission in Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA). Single Center Observational Study
-
Abstract Number: 2744
Mi-RNA Profile of Active Vascular BEHÇET’S Patients
-
Abstract Number: 2746
The Importance of the Serum Visfatin Levels in Behcet’s Disease Patients
-
Abstract Number: 2747
Identification of Potential Serum Biomarkers for Behcet Disease By High Resolution Quantitative Proteomic Analysis
-
Abstract Number: 2748
Microparticles May Play a Role in Causing Thrombosis in Behçet’s Syndrome and Act As a Biomarker for Risk Management
-
Abstract Number: 2749
The Clinical Course of Acute Deep Vein Thrombosis of the Legs in Behçet’s Syndrome
-
Abstract Number: 2750
Effects of Anticoagulant Treatment on the Incidence of New Vascular Events in Patients with Behcet’s Disease with Vascular Involvement
-
Abstract Number: 2751
18F-FDG PET/CT in Vascular Disease Due to Behçet’s Syndrome
-
Abstract Number: 2752
Budd-Chiari Syndrome Due to Behçet’s Syndrome: Some Patients Present without Liver Related Symptoms and Have a Better Outcome
-
Abstract Number: 2753
Reduced Heart Rate Variability in Patients with Behcet’s Disease
-
Abstract Number: 2754
Predictors of Quality of Life in Behçet’s Syndrome
-
Abstract Number: 2755
Disease Activity and Quality of Life in BEHÇET’S Disease: The Role of Patients Reportedoutcomes
-
Abstract Number: 2756
Treatment of Mucocutaneous Manifestations in Behçet’s Disease with Anakinra: A Pilot Open-Label Study
-
Abstract Number: 2757
Efficacy and Safety of ANTI-TNF ALPHA in BEHÇET Disease: A International Multicenter Registry of 122 Patients
-
Abstract Number: 2758
Predictive Factors for the Response to Infliximab Therapy in Patients with Behçet’s Disease
-
Abstract Number: 2759
Anti-TNF Treatment for Refractory Vascular Involvement of Behçet’s Syndrome
-
Abstract Number: 2760
Interferon Alfa-Associated Depression in Patients with Behçet’s Syndrome
-
Abstract Number: 2761
Increased Risk of Parenchymal Neurological Involvement in Behcet’s Syndrome Patients with Panuveitis
-
Abstract Number: 2762
Atrophy of Hippocampal Region in Chronic Progressive Neuro-Behçet’s Disease
-
Abstract Number: 2763
Long-Term Outcome of Chronic Progressive Neurological Manifestations in Behcet’s Disease
-
Abstract Number: 2764
S100B Astrocyte Protein May Serve As a Prognostic Factor in Reversible Cerebral Vasoconstrictive Syndromes
-
Abstract Number: 2765
Putative Blood Biomarkers of Reversible Cerebral Vasoconstriction Syndrome
-
Abstract Number: 2766
Mycophenolate Mofetil in the Treatment of Primary Central Nervous System Vasculitis
-
Abstract Number: 2767
Core Outcome Domains and Potential Measurement Instruments in polymyalgia Rheumatica (PMR) Using Omeract Filter 2.0
-
Abstract Number: 2768
Patient Reported Outcomes and Acute Phase Reactants in Polymyalgia Rheumatica in Patients Treated with Prednisone Versus Modified-Release Prednisone
-
Abstract Number: 2769
Validation of New 2012 EULAR/ACR Classification Criteria for Polymyalgia Rheumatica: Comparison with the Previous Criteria in a Prospective Multi-Center Study
-
Abstract Number: 2770
Polymyalgia Rheumatica Relapse and “Silence” Large Vessel Vasculitis. Is There Any Association?
-
Abstract Number: 2771
PET-CT Imaging and Association of Ferritin Autoantibodies in Polymyalgia Rheumatica
-
Abstract Number: 2772
The Use of Imaging in the Diagnosis of Polymyalgia Rheumatica: Systematic Literature Review and Meta-Analysis
-
Abstract Number: 2773
Whole-Body MRI Reveals Characteristic Extracapsular Pattern of Inflammation in Polymyalgia Rheumatica
-
Abstract Number: 2774
Why Leg Ulcers Do Not Heal? a Prospective Study Showing High Proportion of Small Vessel Vasculitis
-
Abstract Number: 2775
Cutaneous Vasculitis Associated with Severe Bacterial Infections. Study of 27 Patients from a Series of 766 Cutaneous Vasculitis
-
Abstract Number: 2776
Drug-Associated Cutaneous Vasculitis: Study of 239 Patients from a Single Referral Center
-
Abstract Number: 2777
Clinical-Biological Spectrum and Therapeutic Management of Hypocomplementemic Urticarial Vasculitis: Data from a French Nationwide Study on 57 Patients
-
Abstract Number: 2778
Non-Systemic Vasculitic Neuropathy: Presentation, Therapeutic Management and Outcome